Supernus Pharmaceuticals Inc
$ 47.64
1.88%
07 Aug - close price
- Market Cap 2,771,123,000 USD
- Current Price $ 47.64
- High / Low $ 47.88 / 46.43
- Stock P/E N/A
- Book Value 17.73
- EPS -1.92
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -0.10 %
- 52 Week High 59.68
- 52 Week Low 40.32
About
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$62.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-05 | 2026-02-24 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-25 | 2024-11-04 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-08 |
| Reported EPS | 0.39 | 0.21 | 0.8821 | 0.61 | 0.91 | 0.44 | 0.5483 | 1.1 | 0.67 | 0.24 | 0.89 | 0.24 |
| Estimated EPS | 0.3 | 0.28 | 0.41 | 0.82 | 0.47 | 0.37 | 0.52 | 0.44 | 0.39 | 0.38 | 0.55 | 0.08 |
| Surprise | 0.09 | -0.07 | 0.4721 | -0.21 | 0.44 | 0.07 | 0.0283 | 0.66 | 0.28 | -0.14 | 0.34 | 0.16 |
| Surprise Percentage | 30% | -25% | 115.1463% | -25.6098% | 93.617% | 18.9189% | 5.4423% | 150% | 71.7949% | -36.8421% | 61.8182% | 200% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SUPN
2026-08-08 13:10:46
Argus has lowered its target price for Supernus Pharmaceuticals Inc. (SUPN) to $41.00, while the current stock price is $47.64. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system diseases. Investors can access the full report with a Yahoo Finance Silver subscription.
2026-08-08 12:10:46
Zacks Research has upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from a "hold" to a "strong-buy" rating. This upgrade comes despite a broader analyst consensus of "Moderate Buy" with a target price of $62.83. The company, which specializes in central nervous system therapies, also saw several institutional investors, including Millennium Management, significantly increase their holdings in Q1.
2026-08-07 21:24:00
This article provides access to a slide deck published by Supernus Pharmaceuticals, Inc. concerning an M&A call related to Indivior Pharmaceuticals, Inc. The content is presented by SA Transcripts, a team responsible for developing and publishing earnings call transcripts on Seeking Alpha.
2026-08-06 10:09:54
Supernus Pharmaceuticals, Inc. announced positive earnings pre-announcements, updating its fiscal year 2026 revenue range from $840-$870 Million to $860-$890 Million. The company has been active in mergers and acquisitions, including a proposed merger with Indivior and an acquisition of Sage Therapeutics, and has seen various FDA approvals and clinical trial developments for its treatments.
2026-08-05 12:46:04
Supernus Pharmaceuticals, Inc. has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance from an estimated $840-$870 million to $860-$890 million. This update highlights the company's financial performance and future projections. The article also provides a list of recent news related to Supernus, including mergers, quarterly results, and FDA approvals.
2026-08-04 12:57:00
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on the central nervous system (CNS). The combined entity, which will operate under the name Supernus Inc. and trade on Nasdaq under 'SUPN', expects pro forma net revenue of $2.2 billion and $125 million in annual cost synergies. The merger will create a portfolio of 11 medicines for neurology, addiction, and psychiatry, with current Supernus CEO Jack Khattar leading the new company.
